Biovista's BVA-201 drug for MS shows positive results

Editorial Checklist Reviewed
Sep 10 2009NewsGuard 100/100 Score

Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS.

"This is our second success in MS in a period of 6 months, with BVA-201 showing efficacy levels closely comparable to those of dexamethasone," said Aris Persidis, Ph.D., President of Biovista. "Histology results are also encouraging, since they seem to confirm our expectations regarding the compound's mechanism of action. What is even more important is that BVA-201 has a known and very favorable safety profile and is already approved for chronic use," Dr. Persidis added.

Source:

http://www.biovista.com/

Posted in: Pharmaceutical News

Tags: , , , , , , , , , , , ,

Comments (0)

Suggested Reading

New study could lead to a more potent treatment option for multiple sclerosis
Saturated fats accelerate neurodegeneration in multiple sclerosis
Multiple sclerosis drug could help individuals with reduced working memory
New EULAR recommendations provide updated treatment strategies for systemic sclerosis
Phase 2 study evaluates safety and efficacy of asunercept in COVID-19 patients
Mitochondrial genetics shed light on ALS Risk and protection
Research identifies crucial links between dietary choices and progression of multiple sclerosis
Identical twins study uncovers insights into multiple sclerosis mechanisms

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Medical and behavioral interventions can reduce fatigue in people with multiple sclerosis